Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Protein C as a surrogate end-point for clinical trials of sepsis. | Available online http content 12 2 139 Commentary Protein C as a surrogate end-point for clinical trials of sepsis Kathleen D Liu1 and Michael A Matthay2 1 Divisions of Nephrology and Critical Care Medicine Department of Medicine University of California 521 Parnassus Ave C443 San Francisco CA 94143 UsA 2Departments of Anesthesia and Medicine and the Cardiovascular Research Institute University of California 505 Parnassus Ave Moffitt Hospital Room M-917 San Francisco CA 94143-0624 USA Corresponding author Michael A Matthay Published 24 April 2008 This article is online at http content 12 2 139 2008 BioMed Central Ltd Critical Care 2008 12 139 doi cc6859 See related research by Shorr et al. http content 12 2 R45 Abstract Identification of good surrogate end-points can greatly facilitate the design of clinical trials. Using data from PROWESS and ENHANCE Shorr and colleagues explore the potential value of several plasma biomarkers for treatment trials of activated protein C for severe sepsis. Based on the framework proposed by Vasan they tested the utility of several factors protein C interleukin-6 antithrombin III prothrombin time protein S and d-dimers as type 0 1 and 2 biomarkers. Only protein C had acceptable performance characteristics as a type 2 biomarker or surrogate end-point. The utility of protein C as a surrogate end-point for studies of severe sepsis must be validated in future prospective studies. In this issue of Critical Care Shorr and colleagues 1 tested the potential value of surrogate markers for the treatment of patients with severe sepsis with activated protein C also known as Drotrecogin alfa activated DrotAA using data from the PROWESS Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis and ENHANCE Extended Evaluation of Recombinant Activated Protein C clinical trials. PROWESS 2 was a double-blind randomized clinical trial of DrotAA for the treatment of
